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Malignant Pleural Mesothelioma (MPM) is typically diagnosed 20–50 years after exposure to
asbestos and evolves along an unknown evolutionary trajectory. To elucidate this path, we
conducted multi-regional exome sequencing of 90 tumour samples from 22 MPMs acquired
at surgery. Here we show that exomic intratumour heterogeneity varies widely across the
cohort. Phylogenetic tree topology ranges from linear to highly branched, reflecting a steep
gradient of genomic instability. Using transfer learning, we detect repeated evolution,
resolving 5 clusters that are prognostic, with temporally ordered clonal drivers. BAP1/−3p21
and FBXW7/-chr4 events are always early clonal. In contrast, NF2/−22q events, leading to
Hippo pathway inactivation are predominantly late clonal, positively selected, and when
subclonal, exhibit parallel evolution indicating an evolutionary constraint. Very late somatic
alteration of NF2/22q occurred in one patient 12 years after surgery. Clonal architecture and
evolutionary clusters dictate MPM inflammation and immune evasion. These results reveal
potentially drugable evolutionary bottlenecking in MPM, and an impact of clonal architecture
on shaping the immune landscape, with potential to dictate the clinical response to immune
checkpoint inhibition.
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MPM is a rare, incurable cancer that carries a dismalprognosis. Its incidence is increasing globally despite itsprimary cause, asbestos exposure, having been known
for over 50 years1. The global annual incidence is 7–40 per mil-
lion, with an estimated annual death rate of 38,4002 which is set
to increase due to continued asbestos use. MPM typically grows
to enormous volumes averaging 640 ml3, and exhibits wide var-
iations in tumour aggressiveness. This universally lethal cancer
has seen only very limited drug development over the last two
decades, with the exception of combination immune checkpoint
inhibition4. Personalised treatments are lacking for MPM5,
however recent insights into the inter-patient genomic hetero-
geneity of this cancer have revealed frequent somatic alterations
involving the cancer genes BAP1, NF2 and CDKN2A6,7. Pre-
clinical models have implicated these tumour suppressors as
initiators of MPM8,9 with prognostic significance, particularly
when they are concurrent10.
Major questions remain however regarding the extent and
clinical significance of genomic intratumour heterogeneity (ITH)
in MPM, and in particular whether constrained, temporal
ordering of driver events is required for MPM transformation;
critical information that could help to inform the development of
precision therapy5,11.
Clinical phylogenetic studies such as TRACERx lung12 have
shown that clonal neoantigen architecture drives immune
surveillance13 which in turn is a selection pressure leading to
immune evasion via immunoediting14,15. However, it is not
known to what extent ITH modulates host immune surveillance
or immune escape in MPM.
In this work, to address these gaps in knowledge, we establish a
patient-focused research platform named mesothelioma evolu-
tion: deciphering drugable Somatic alterations (MEDUSA), in
order to infer a human evolutionary model of MPM tumor-
igenesis and understand the inter-relationships that exist between
genomic ITH, host immune surveillance and clinical phenotype,
as well as providing a platform for deriving preclinical models to
underpin pharmacogenomic investigations. Here we show that
clonal architecture in MPM affects patient survival and compo-
sition of the tumour microenvironment.
Results
We conducted multi-regional whole-exome sequencing of 90
tumour regions from 22 patients (the MEDUSA22 cohort)
undergoing routine surgery by extended pleurectomy decortica-
tion. Matched DNA isolated from whole blood served as a
germline reference for calling somatic events. Sampled regions
(4–5 per patient) were anatomically stereotyped across the entire
cohort, comprising the apex (R1), pericardium (R2), anterior and
posterior costophrenic recesses (R3 and R4) and the oblique fis-
sure (R5; Fig. 1a). Most patients (17/22, 74%) had epithelioid
histology with the remaining five patients having biphasic MPM
(supplementary data 1 and supplementary fig. 1). The majority of
patients were chemonaïve with the exception of one patient, who
received neoadjuvant chemotherapy. The cohort exhibited
extensive inter-patient and intratumour heterogeneity consistent
with a steep gradient of genomic instability (Fig. 1b).
Median sequencing depth across all regions was 261x (range
173–469), median coverage breadth was 99.9% (97–100), with a
median tumour purity of 46.5% (18–90; supplementary data 2
and 3). We identified 3523 unique somatic mutations across all
the patients in our cohort (single-nucleotide variants and indels)
of which 1335 were coding mutations. Total mutation burden was
low, 1 mutation/megabase (mt/Mb range 0.4–1.6). Clonal muta-
tion burden was 0.6 mut/Mb (0–0.6) and subclonal mutation
burden 0.6 mut/Mb (0.0–1.1). The median number of mutations
per patient in our cohort was 130 mutations (range 86–204) of
which a median of 71.5 mutations (42–116) were clonal and 53
mutations (9–120) were subclonal (supplementary fig. 2). The
per-patient mutation burden for the cohort is detailed in sup-
plementary data 4.
MPM trees inferred by clonal deconvolution were categorised
into two, broad topological classes (supplementary figs. 3A-V and
4, and supplementary data 5). Linear trees were characterised by
monophyletic clones, all arising from a common node (or most
recent common ancestor). In contrast, branched trees comprised
polyphyletic clones arising from subclonal nodes16,17. The
majority (64%) of MPMs were classed as linear, defined by the
absence of subclonal branching (Fig. 1c and supplementary fig. 4),
which correlated with both the subclonal mutation (Wilcoxon
p= 0.003) and SCNA burden (Wilcoxon p= 0.0034, Fig. 1d).
We temporally dissected mutational processes operating dur-
ing early (clonal or ubiquitous somatic events) versus late stages
of evolution following subclonal diversification12,18. The nucleo-
tide transition C→T was the most common clonal and subclonal
base substitution, resulting from deamination of 5-methylcytosine
(supplementary fig. 5A). In contrast, subclonal enrichment was
most commonly associated with C→A transversion. Mutational
signatures inferred using deconstructSigs19 showed clonal
enrichment of clock-like, base excision repair deficiency and
single base substitution signatures SBS16, SBS19, SBS32 and
SBS3920, reflecting underlying mutagenesis mechanisms involved
in early MPM evolution (supplementary fig. 5A). There was a
paucity of subclonal signatures in the cohort with only SBS42
(haloalkanes) showing enrichment during later evolution (sup-
plementary fig. 5B).
Elucidation of cancer genes undergoing positive selection, and
therefore operating as likely drivers during early evolution of
MPM, was achieved by computing the ratio of clonal non-
synonymous to synonymous mutations, normalised by gene size
(dN/dS analysis)21. Clonal positive selection (dN/dS>1) involved
five tumour suppressors NF2, BAP1, SETD2 which were inde-
pendently validated in the mesothelioma TCGA7, FBXW7 and
PRELID1 (supplementary fig. 6 and supplementary data 6 and 7).
In contrast, subclonal positive selection was only associated with
NF2 (14%).
The majority of driver mutations were predicted as deleterious,
loss of function events and were enriched in tumour suppressor
genes (supplementary fig. 7A and supplementary data 8). MPMs
harboured a median of two clonal driver mutations per patient
(range 0–6), with BAP1 being the most frequent, involving eight
patients (36%, comparable to the TCGA’s reported 38%). Co-
occurrence of multiple driver mutations was common with a
median 2 (0–6). Patient MED91 harboured the highest number of
drivers, totalling 6.
To establish if clonal driver mutations could be detected (and
orthogonally validated) in plasma, we developed patient-specific
digital droplet PCR assays to screen the circulating free DNA of
11 patients. Although the rate of detection was low with 4/11
patients positive (36%), overall survival was significantly worse
for those patients in whom circulating free DNA could be
detected, logrank p= 0.020 (Fig. 2a and supplementary data 9–
11). The presence of circulating tumour DNA was significantly
associated with NF2 mutation (p= 0.015 Fig. 2b), loss of 1p36.11
loss (p= 0.015) and/or 6q25.1-2 (p= 0.018) and lack of lymph
node involvement (p= 0.024, Fisher’s exact test), supplementary
fig. 7B and supplementary data 9–11.
Secondary tumour suppressor hits leading to bi-allelic inacti-
vation of drivers by either mutation and/or copy number loss
were more common during early evolution. A median of 1 gene
per MPM (0–2) was involved in a clonal double-hit inactivation
(supplementary fig. 7C and supplementary data 9). These double-
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hit events were significantly enriched in tumour suppressor genes
compared with other genes and agreed with the mesothelioma
TCGA. Clonal second hit events most frequently involved NF2 in
7 MPMs, followed by BAP1 in 6 MPMs and SETD2 in 3 MPMs
(supplementary fig. 7D). Germline BAP1 has been reported
previously22 but this was not identified in BAP1 bi-allelic inac-
tivation in this cohort. Subclonal bi-allelic inactivation commonly
involved BAP1 and the Hippo pathway genes NF2 (MED34) and
LATS1 (MED3), (supplementary fig. 7D).
To explore the impact of driver evolution on MPM progres-
sion, we conducted longitudinal biopsies and copy number ana-
lysis of a patient who had exceptionally indolent MPM exhibiting
a 12-year progression-free survival interval following radical
surgery. Subclonal NF2 copy number loss was observed at the
time of radiological progression, and this coincided with both a
higher burden of copy number alterations and chemoresistant
MPM, suggesting late stage subclonal expansion, and Hippo
pathway inactivation coincident with clinically more aggressive
growth and drug resistance (Fig. 2b).
In contrast to the low mutation burden in this cohort, copy
number alterations involved almost a quarter of the exome 24.71%
(range 12.76–92.58) of which the majority were clonal, 21.32%
(1.17–63.22) and 4.91% (0.1–29.36) were subclonal (supplementary
data 12 and 13). Copy number losses, estimated and cross validated
using 5 algorithms and by array based analysis (supplementary
fig. 8), were significantly more common than gains across the
cohort (Fig. 2c, supplementary fig. 9 and supplementary data 12
and 13).
Clonal amplification was observed in three cytobands including
16p11.2 which encompasses the oncogenic transcription factor
gene FUS23 commonly involved in translocations associated with
myxoid liposarcoma, 17q21.31, and 17q22-23 which encompasses
the E3 ubiquitin ligase substrate binding adaptor gene SPOP24,25,
most commonly mutated in prostate cancer (supplementary
figs. 1 and 10A, B). The most frequent clonal gains involved 8p24
in 3 MPMs (13%). This region spans NDRG1 which stabilises
methyltransferases involved in DNA repair, and also RECQL4
which plays a crucial role in the end resection step of homologous
recombination. Only one patient had 8p24 gain as a subclonal
event suggesting that this event is restricted to the earlier phase of
MPM evolution.
MPMs showed evidence of allelic heterogeneity, with clonal
copy number alterations mirroring positively selected clonal
mutations. The most frequent was -22q (NF2) in 82% of MPMs,
followed by 9p21.3 (CDKN2A and MTAP), and 3p21.3 (BAP1),
(supplementary fig. 1 and supplementary data 12 and 13). We






Fig. 1 Genomic intratumour heterogeneity in MPM. A Pleural mesothelioma tissue sampling locations were consistent between patients involving the
apex (region1, R1), the pericardium (R2), anterior costophrenic angle (R3), posterior costophrenic angle (R4) and the oblique fissure (R5). The rationale for
selecting the anatomically sterotyped sites at the time of tissue sampling was to ensure maximum coverage of the tumour from superior to inferior; medial
to lateral; and anterior to posterior. We chose the oblique fissure (R5) as this is common to both the right and left lung and could be a reliable anatomical
site bilaterally. Spatial evolution of mesothelioma would be expected to be best reflected in samples at maximum distance from one another, reflecting the
inherent intratumour heterogeneity. These regions are represented by the most superior region (R1) and the inferior (R3 and R4). B Inter-patient and
intratumour heterogeneity in the MEDUSA22 cohort. Histograms summarising the variance in clonal versus subclonal mutations (left) compared with
somatic copy number alterations (SCNAs, right). Left top, relative number of mutations, left bottom, proportion of mutations ranked by clonal mutation
proportion ranging from maximum (left) to minimum (right). Right top, ratio of truncal SCNA versus branch SCNA. Right bottom, relative proportion of
SCNA ranked as for mutations. C Spectrum of subclonal diversity in the MEDUSA22 cohort, ranging from linear topology (MED33 left) to branched
(MED12 right). Centre, Pie chart showing the relative proportion of patients in the MEDUSA22 cohort classified as either linear (64%) or branched (36%).
D Box plots showing the positive correlation between topology classified as either linear or branched, and subclonal SCNA count (two-sided
Mann–Whitney U test p= 0.034, left) and subclonal mutation count (two-sided Mann–Whitney U test p= 0.003, right). n= 22 patients. Both box plots
denote medians (centre lines), 25th and 75th percentiles (bounds of boxes), and minimum and maximum (whiskers).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-21798-w ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:1751 | https://doi.org/10.1038/s41467-021-21798-w |www.nature.com/naturecommunications 3
orthogonally validated functional inactivation of the hippo
pathway by confocal microscopy in paired exome sequenced
primary cell lines grown from MEDUSA MPMs. Clonal NF2
deletion was present in the cell line MED85 and this was asso-
ciated with constitutive nuclear translocation of YAP, compared
with MED96 which harboured wild-type NF2 (Fig. 2d). Across
the cohort, alternative modes of Hippo pathway inactivation were
observed involving LATS1 (35% clonal versus 11% subclonal),
and LATS2 (32% clonal versus 18% subclonal), (supplementary
figs. 1 and 7D).
Clonal copy number events frequently involved arm-level losses
more frequently than gains, occurring at higher frequency on
chromosome 4p and q, 9p and 22q (Fig. 2e and supplementary
data 14). We did not identify whole-genome haploidisation7 or
whole-genome doubling26 in this cohort. Copy-neutral loss of
heterozygosity (CN LOH also referred to as uniparental disomy)
involving duplication of an allele with concurrent loss of the other
allele, occurred in 12 patients of which 11 events were restricted to
chromosome 9 (supplementary fig. 11 and supplementary data 15).
Clonal homozygous deletion involving the region 9p21.3,
which harbours the tumour suppressors cyclin-dependent kinase
inhibitor 2A and B (CDKN2A/B) and methylthioadenosine
phosphorylase (MTAP), was found in seven patients (32%).
Homozygous deletion only ever occurred as a clonal event,
whereas subclonal heterozygous loss was seen in six
patients (26%).
With the exception of 9p21.3, clonal homozygous deletions
were otherwise rare, involving 3p21 (BAP1) in only one patient.
Mirrored subclonal allelic imbalance (MSAI) involving spatially
distinct, reciprocal copy number losses was a rare event, occur-
ring in only one MPM in 10q23 (PTEN) consistent with parallel
evolution (supplementary fig. 12).
One MPM (MED109) exhibited no driver single nucleotide
variants (SNVs) or INDELs, had more copy number gains than
losses, and had clonal deletions involving multiple drivers
CDKN2A and NF2. In addition, this patient also had deletion of
ID3 (1p36.12), and a region spanning 14q11-14q32 harbouring
the genes CCNB1IP1 (14q11.2), BAZ1A, NKX2-1 (14q13), MAX,
RAD51B (14q23-24), DICER1, and BCL1B as well as -22q
encompassing LZTR1, ZNRF3, MYH9, APOBEC3B, MRTFA,
PATZ1, EP300 and CHEK2 (supplementary fig. 1 and supple-
mentary data 13).
The clonal mutation order associated with early evolution of
MPM is unknown. We applied transfer learning27 to de-noise and
structurally correlate trees across the MEDUSA22 cohort (sup-
plementary fig. 13) in order to determine whether MPMs shared






















Fig. 2 NF2/22q loss correlates with detectable ctDNA and late progression in MPM. A Left. Kaplan-Meier plot showing the relative survival of patients
with detectable, clonal driver mutations present in the circulating tumour DNA (ctDNA). Overall survival was significantly lower for patients positive for
ctDNA (Two-sided Log-rank test p= 0.020; hazard ratio 5.20; 95% confidence intervals: 1.12, 24.09). Right. Column chart showing that patients who had
detectable ctDNA (black column) were more likely to have a NF2 mutant tumour (two-sided Fisher’s exact test p= 0.015; Odds ratio is infinite because all
ctDNA-positive tumours were NF2 mutants; 95% confidence intervals: 1.27, infinite). n= 11 patients. B Longitudinal sampling of tissue from a patient taken
at the time of radical pleurectomy decortication (this patient was not enroled into MEDUSA). Array based SCNA analysis was conducted showing
subclonal loss of 22q at first progression with a higher SCNA burden, ~12 years following surgery. Subsequent progression was associated with drug
resistance (CT scan top right). The squares at the base show copy number losses in blue and gains/amplifications in red. The time from final progression to
death was 29 days. C Stacked mountain plot summarising clonal versus subclonal losses (above, green) compared with gains (orange/truncal, red/branch)
below. This figure shows the relative frequency (y axis) of copy number losses compared with gains along the whole-exome (x axis) averaged across the
cohort of patients. D Nuclear YAP expression in a cell line derived from patient MED85 harbouring deletion of NF2, compared with wild-type NF2 (MED96)
showing non-nuclear YAP expression (right panel). Confocal images: FV1000 (Olympus), ×60 objective, ×4 zoomed scale bars= 10 μm. E Heatmap
summarising arm level losses in the MEDUSA22 cohort by chromosome (left column). The clonal (blue) versus subclonal (grey) frequency of arm level
losses per chromosome are shown in the histogram on the right.
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common evolutionary trajectories with a constrained clonal
mutation order, and to define critical bottlenecks28 during evo-
lution that could serve as potential targets for stratified therapy.
Integrating both clonal SCNA and SNV driver events, 5 evolu-
tionary clusters were delineated, ranging from low complexity
(cluster 1) to the most complex (cluster 5 Fig. 3a, c). A Jackknife
procedure was used to estimate MPM evolutionary cluster sta-
bility (supplementary fig. 14)27.
Notably the largest cluster C5, which exhibited the largest
number of repeated early clonal transitions, and featured frequent
FBXW7 mutation (supplementary fig. 6) secondary to 9p21 loss,
was associated with the shortest median progression free survival
(logrank p= 0.013) and overall survival (logrank p= 0.005
Fig. 3b). We utilised a decision tree to bin MPMs into evolu-
tionary clusters from the tumour genome Atlas, and confirmed a
poorer prognosis for C5 (supplementary fig. 15 and supplemen-
tary data 16). Notably, in both the MEDUSA22 cohort and
TCGA, C5 was restricted entirely to the epithelioid subtype
(supplementary data 16).
Allelic heterogeneity associated with either BAP1 or its locus
3p21 was a repeated, universally early event during MPM evo-
lution involving 2 out of 5 evolutionary clusters (C4 and C5).
Cluster C2 was an outlier exhibiting chromosome 4 loss (-chr4)
defined by at least 60% loss of the whole chromosome and which
encompassed FBXW7(4q31.3). This was the only repeated early
clonal event in cluster C2, but was also associated with other early
clonal events in C3, C4 and C5 suggesting a frequent and critical
role for this macroevolutionary event during MPM tumorigenesis.
A consistent feature across the evolutionary clusters was the
timing of hippo pathway inactivation signified by either loss of
22q or NF2 mutation. This was frequently found to be a late
clonal event involving all clusters except C1.
The tumour microenvironment was modulated by the degree
of exonic ITH with evidence of genomic immune evasion
implicating an interplay between host immunity and MPM evo-
lution. Evolutionary cluster C5 was associated with higher CD8 T
lymphocyte infiltration (Fig. 4a). The MEDUSA22 cohort showed
a wide inter-patient variability in predicted neoantigen burden
averaging 15 per patient (range 0–27) of which the majority were
clonal, with a median of 12 neoantigens per patient (0–26),
compared to subclonal neoantigens which averaged 1/patient
(range 0–14; Fig. 4b). Neoantigens were recurrent in 6 genes
including two drivers: SETD2 which was the most common
(32%), and LATS2, as well as XIRP2, TMEM104, TTN and
TME1L1 (supplementary data 17). Subclonal neoantigen burden
was associated with lower immunosuppressive regulatory T cell
infiltration, as assessed by transcriptome-based digital cytometry
(Wilcoxon p= 0.018, Fig. 4c).
Tumours achieve immune escape from cytolytic T cell
immunosurveillance, in part via loss of heterozygosity (LOH) of
the human leucocyte antigen (HLA) cluster, an immunoediting
strategy that reduces antigen expression via the major histo-
compatibility complex (MHC), to escape T cell receptor-
dependent CD8 lymphocyte mediated tumour suppression.
HLA LOH was found in five patients and was always subclonal































































Fig. 3 Defining evolutionary trajectories and their prognostic significance in MPM. A Heatmap showing the evolutionary clusters inferred by transfer
learning and hierarchical classification. In the middle of the heatmap, five evolutionary clusters are defined and are vertically colour coded, with cluster 1
(C1) in red, C2 blue, C3 green, C4 purple and C5 orange (shown in the key on the right). On the left side of the heatmap, individual evolutionary transitions
(i.e. mutational events including both SCNAs and mutations) are shown on the lower axis. The abbreviation GL corresponds to germline. Any transition
occurring more than three patients is considered a repeated evolutionary transition. On the right the presence or absence of a mutation or copy number
loss is shown. On the right, the probability of an event is presented by the shade of blue, with probability= 1 being dark blue. B Kaplan-Meier curves
showing (left) shorter progression-free (two-sided Log-rank test p= 0.013; hazard ratio 3.52; 95% confidence intervals: 1.22, 10.13) and (right) lower
overall survival (two-sided Log-rank test p= 0.005; hazard ratio 4.43; 95% confidence intervals: 1.42, 13.77) of C5 MPMs compared to other evolutionary
clusters (C1–C4). n= 22 patients. C Inferred evolutionary trajectories involving repeated transitions in more than three patients. Somatic events that are
exclusively early clonal (germline (GL) transitions) are encompassed by a light blue area. Conversely, exclusively late clonal transitions are highlighted in
red. The specific number of patients exhibiting repeated transitions is shown as numbers against the directed edges (transitions).
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restricted to later stages of MPM evolution following exomic
diversification. Higher subclonal neoantigen burden was asso-
ciated with HLA LOH (Wilcoxon p= 0.023, Fig. 4d) and time to
progression following surgery (Fig. 4e, logrank p= 0.019). MPMs
harbouring high clonal copy number burden exhibited greater
systemic inflammation reflected by Neutrophil:lymphocyte and
platelet:lymphocyte ratios (Fig. 4f).
Discussion
Mesotheliomas are uniquely created following exposure to
asbestos1. The evolutionary path taken unfolds over several dec-
ades to manifest as an enormous cancer that typically grows
contiguously to invade local structures, rather than exhibiting
distant metastatic behaviour. Our study reveals extensive exomic
variation both between and within patients with MPM. This may
be reflected clinically in the broad spectrum of MPM phenotypes
that extend from highly indolent to aggressive and rapidly pro-
liferative. Epithelioid MPMs are considered the least aggressive
histological subtype, compared with sarcomatoid and biphasic
MPM. In this study, transfer learning revealed a prognostic
cluster C5 which had the most complex evolutionary trajectory
and was associated with a shorter survival. In the MEDUSA22
cohort, C5 was entirely epithelioid, consistent with a recent study
that has reported the use of deep learning to identify poor
prognostic epithelioid MPMs29.
Loss of chromosome 4, 3p21 and 9p21.3 were consistently
found to be early clonal events, likely involved in initiation. BAP1
is encoded by 3p21 and is a tumour suppressor gene that encodes
a nuclear deubiquitinase that regulates histone H2A to regulate
transcriptional repression. BAP1 mutation or 3p21 loss was
predominantly heterozygous, with evidence of clonal and sub-
clonal second hits leading to its complete inactivation. BAP1 has
been reported to suppress the polycomb repressive complex
PRC2 and its inactivation results in upregulated EZH2 mediated
trimthylation of histone H3 (H3K27me3s). Targeting the PRC2
catalytic core (EZH2) with specific small molecule inhibitors may
be synthetic lethal to MPMs, as supported pre-clinically30. We
reported a clonal BAP1 mutation rate of 36%, similar to that
reported in the TCGA7. However, minute deletions revealed by
single region high density comparative genomic hybridisation
array, combined with next-generation sequencing implicates a
generally higher rate of BAP1 somatic alterations in MPM31.
Our findings suggest that loss of chromosome 4 is a repeated
event during early evolution of MPM. FBXW7 is encoded at
4q31.3 and was identified as a positively selected tumour sup-






Fig. 4 Clonal architecture shapes the immune microenvironment in MPM. A Left. Representative immunofluorescence micrographs contrasting cluster
C2 CD8+ exclusion (“COLD”, MED75) with a highly infiltrated C5 tumour (“HOT”, MED35). Yellow: CD8; Red: Pan-Cytokeratin; Blue: DAPI (nuclei).
Original magnification ×400. Scale bars represent 50 μm. Right. Higher CD8+ T-cell infiltration associated with evolutionary cluster C5 by cell count (Two-
sided Mann–Whitney U test p= 0.032) and Pan-Cytokeratin to CD8 distance (two-sided Mann–Whitney U test p= 0.043). n= 15 patients. Both box plots
denote medians (centre lines), 25th and 75th percentiles (bounds of boxes), and minimum and maximum (whiskers). B Histogram showing the relative
number of neoantigens across the MEDUSA22 cohort, colour coded as either clonal (blue) or subclonal (orange) ranked from maximum (left) to minimum
(right). C Left. Stacked column chart summarising the relative proportion of tumour infiltrating leucocytes enumerated by digital cytometry using
CIBERSORT. Right, box plot showing a significantly higher Treg abundance in MPMs with lower neoantigen diversity (two-sided Mann–Whitney U test
p= 0.018). n= 18 patients. Box plot denotes median (centre line), 25th and 75th percentiles (bounds of box), and minimum and maximum (whiskers).
D Box plot showing increased neoantigen intratumour heterogeneity (ITH) in patients with evidence of HLA LOH (two-sided Mann–Whitney U test p <
0.023). n= 22 patients. Box plot denotes median (centre line), 25th and 75th percentiles (bounds of box), and minimum and maximum (whiskers).
E Kaplan-Meier plot showing significantly lower mortality for patients with a higher burden of subclonal (shared) neoantigens (two-sided Log-rank test p=
0.019; hazard ratio 3.14; 95% confidence intervals: 1.16, 8.51). n= 22 patients. F Box plots showing a significant interaction between clonal SCNA burden
versus neutrophil-lymphocyte ratio (NLR, left, two-sided Mann–Whitney U test p= 0.004) and platelet-lymphocyte ratio (PLR, right, two-sided
Mann–Whitney U test p= 0.009). n= 22 patients. Both box plots denote medians (centre lines), 25th and 75th percentiles (bounds of boxes), and
minimum and maximum (whiskers).
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FBXW7 is negatively prognostic in univariate analysis in the
TCGA and encodes an F box protein family member involved in
phosphorylation-dependent ubiquitination . Its inactivation
upregulates the prosurvival BCL2 family member, MCL1 leading
to resistance to antimicrotubule agents32,33 such as vinorelbine,
which has demonstrated useful clinical efficacy in relapsed
MPM34.
NF2/-22q was found to be a predominantly late clonal event,
suggesting an early evolutionary constraint. NF2 mutation was
positively selected during both early and late evolution. Parallel
evolution involving NF2/-22q implicates a deterministic trajec-
tory in MPM that involves Hippo pathway inactivation, as a key
bottleneck during progression of mesothelioma and this is
implied in an extreme case whereby NF2 loss occurred 12 years
after surgery at the time of progression. The Hippo pathway is
actively being explored as a target for therapy. Although focal
adhesion kinase inhibition has been reported to induce synthetic
lethality in preclinical models, this has not been borne out
clinically35,36. However, targeting oncogenic YAP-driven tran-
scription, ferroptosis, or STRN337 may present an opportunity to
effectively restore Hippo pathway mediated tumour suppression
to treat MPM11,38,39.
Clonal homozygous deletion of CDKN2A was identified in
approximately a third of the MEDUSA22 cohort. Loss of 9p21.3
carries CDKN2A leading to loss of p16ink4a and derepression of
cyclin-dependent kinases 4 and 6 which may serve as a ther-
apeutic target40. Accordingly, we have recently completed a
clinical trial of abemaciclib to test this hypothesis, which has
demonstrated evidence of clinical activity (trials.gov identifier
NCT03654833). MTAP deletion has been reported to confer
sensitivity to inhibition of PRMT541,42 or deprivation of its
substrate s-adenosylmethionine via inhibition of MAT2A43, both
currently clinical drug development targets with potential
in MPM.
We found that MPM evolution shapes the MPM tumour
microenvironment. The most genomically unstable evolutionary
cluster C5 was associated with higher T-cell infiltration and
higher neoantigen burden was associated with immunoediting via
HLA LOH, consistent with immune escape, presumably sec-
ondary to heightened tumour surveillance. Anti-PDL1 immune
checkpoint inhibition has revolutionised the treatment of multi-
ple cancers, with emerging evidence of useful clinical activity in
MPM4,44–46. Our results suggest that clonal architecture mod-
ulates constitutive immune surveillance, antecedent to immune
escape involving HLA LOH. This may highlight a potential
mechanism leading to de novo or acquired immune checkpoint
inhibitor resistance15 in MPM. Our clinicogenomic correlative
studies in clinical trials are underway involving phase II and III47
cohorts to test this hypothesis.
Methods
Ethical and governance approvals. This research was approved by National
ethical committees, under the references 4/LO/1527 (a translational research
platform entitled Predicting Drug and Radiation Sensitivity in Thoracic Cancers –
also approved by University Hospitals of Leicester NHS Trust under the reference
IRAS131283) and 14/EM/1159. Sponsor: The University of Leicester).
Patients and regional tissue sampling. Patients were approached for enrolment
into the MEDUSA cohort if they had a confirmed histological diagnosis of
malignant pleural mesothelioma, and were scheduled for routine surgery involving
extended pleurectomy decortication at the Glenfield Hospital (University of Lei-
cester). Patients were approached 24 h prior to their operation and provided with
patient information regarding the research. All patients signed informed consent
prior to surgery. Following surgery, all patients were longitudinally tracked until
disease progression with CT monitoring. Progression scans were assessed by a
consultant radiologist according to modified RECIST1.1.
During surgery, involving extended pleurectomy decortication (EPD) tumour
tissue was sampled consistently from the same anatomical locations:
(1) Apex
(2) Pericardium
(3) Anterior costophrenic recess
(4) Posterior costophrenic recess
(5) Oblique fissure
A 23-blade scalpels were used to cut up to 10 pieces of tumour tissue measuring
~1.5 cm × 0.5 cm ensuring no cross contamination. Eight pieces of tumour were
placed on cork and two pieces not on cork. All samples were flash frozen in liquid
nitrogen. Cryovials were stored at −80 °C until further use. Hematoxylin and eosin
slides were assessed by a histolopathologist and tumour content scored as a tumour
proportion percentage.
DNA extraction from frozen tissue and blood. The extraction of tumour tissue
DNA was performed using the QiAamp mini kit (Qiagen), according to the
manufacturer’s instructions. Four to six sections were used for each region. Prior to
each EPD, blood was obtained in five 7.5-ml blood tubes containing EDTA. One of
these blood tubes was frozen whole. The remaining four were centrifuged at 226 × g
for 10 min at 4 °C. Following this, the plasma was collected and centrifuged at
402 × g for 10 min at 4 °C. The whole blood, buffy coat and plasma were then
stored at −80 °C until further use. The extraction of germline DNA was performed
using 200 µl of buffy coat and was carried out using the QiAamp DNA blood mini
kit (Qiagen), according to the manufacturer’s instructions. Qubit DNA High
Sensitivity (HS) Assay Kit (Invitrogen) was used to determine quantity DNA.
Samples were prepared according to the manufacturer’s instructions and read on
the Qubit 4 Fluorometer (Invitrogen).
DNA extraction from cell lines. The extraction of DNA was performed from 5 ×
106 cells and was carried out using the QiAamp DNA blood mini kit (Qiagen),
according to the manufacturer’s instructions.
Multi-region whole-exome sequencing. Exome capture and amplification. For
each tumour region and matched germline, the whole-exome sequencing library
was prepared from 1 μg genomic DNA by using the Agilent SureSelect Human All
ExonV6 kit (Agilent Technologies, San Diego, CA).Index codes were added to each
sample. DNA fragmentation (180-280bp) employed hydrodynamic shearing sys-
tem (Covaris, Massachusetts, USA). Remaining overhangs were converted into
blunt ends via exonuclease/polymerase and enzymes removed. After adenylation of
3′ ends of DNA fragments, adaptor oligonucleotides were ligated. DNA fragments
with 3′ and 5′ ligated adaptor molecules were enriched by polymerase chain
reaction (PCR), followed by hybriziation with a biotin labelled probe.
Streptomycin-coated magnetic beads were then used for exon capture, which were
then enriched by PCR to add index tags to prepare for hybrization. Purification
employed the AMPure XP system (Beckman Coulter, Beverly, USA). Quantifica-
tion employed the Agilent high sensitivity DNA assay on the Agilent Bioanalyzer
2100 system.
DNA sequencing. Qualified exome capture libraries were then sequenced on
Illumina NovaSeq 6000 platform, according to standard protocols, for 150 bp
paired-end multiplexed sequence. After sequencing, mean coverage of tumour and
normal exomes were both 276X.
SNV and INDEL calling
Sequence alignment. Raw paired end reads (150bp) in FastQ format were first go
through data quality control process. Reads with adaptor contamination, reads
containing poly-N, and low-quality reads were removed. All the downstream
analyses were based on clean reads that passed quality control. Burrows-Wheeler
Aligner (bwa-0.7.17) was used to align the clean reads to human reference genome
(UCSC hg19) by the mem algorithm with default parameters.
BAM file processing. Mapped genomes were sorted using Sambamba (v0.6.7). We
then used Picard tools (v2.18.9) to merge bam files from the same patient region
and mark duplicate reads. Statistics was done using SAMtools (v1.8).
SNV/InDel calling. Somatic SNVs and INDELs were detected with VarScan2 and
MuTect212. Briefly, VarScan2 somatic (v2.3) were used to do somatic variants
calling between tumour and matched normal samples based on the output from
SAMtools mpileup (1.0)48. Default parameters were used except for the following;
minimum coverage for normal and tumour sample were set to 10 and 8 separately,
minimum variant frequency was adjusted to 0.01 and tumour purity was set to 0.5.
After which VarScan2 processSomatic was used to extract somatic variants with
minimum tumour frequency 0.01 and maximum normal frequency 0.05. Then
bam-readcount (0.8.0) and Varscan2’s wrapped fqfilter.pl were combined to con-
duct the mutation filtering. We used MuTect2 contained in GATK bundle (4.0.5.1)
with default parameters.
All detected variants were annotated with Annovar (14 Dec 2015)49. Main
databases used in future filtering or downstream analysis are as follows: SIFT,
PolyPhen and MutationTaster scores used to predict the deleteriousness of
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mutations; Alternative allele frequencies in populations reported by large scale
sequencing projects 1000 Human Genome(1000G), Exome Aggregation
Consortium(ExAC) and exome sequencing project(ESP); Other databases
including dbSNP, COSMIC, GO and KEGG.
SNV/InDel filtering. To reduce false positive variant calls, further filtering stra-
tegies were used on the mutation detection results of both MuTect2 and VarScan2.
An SNV would be considered a true positive call if it satisfied the following
conditions:
Variant allele frequency. The SNV was called by MuTect2 and VarScan2 (somatic
p-value ≤ 0.1) simultaneously, and both with a variant allele frequency (VAF) no
<2%; or only detected by VarScan2, but with a VAF greater than 5%.
Variant allele frequency in normal samples. VAF in matched normal samples for
the position need to be <1% and reads number for alternative alleles is <5.
Blacklist filter. The SNV was not located in the blacklist, which related to specific
genomic regions like simple repeats and segmental duplications.
Population frequency-based filter. The population frequency of the SNV did not
exceed 1% in any of the following population based database- 1000G, EXAC or
ESP6500, according to the annotation results of Annovar.
Force calling. Multi-regional sequencing allowed the opportunity to increase the
sensitivity to detect variants with low frequency. For a somatic mutation that was
not detected ubiquitously across all tumour regions in a patient, reads information
was extracted from corresponding bam files of each region which with a negative
call, by using bam-readcount (0.8.0)12. In such cases, if mapping quality >20 and
VAF >2%, this site was treated as a positive call.
Indel filtering. For InDel filtering, the blacklist filter and population frequency-
based filter were the same as described as above. VAF threshold was set to 5% for
VarScan2 with somatic p-value ≤ 0.05, total read depth was set >50, alternative read
depth >10 in tumour samples and <2 in corresponding normal samples.
Sample contamination using CONTEST. ContEst (1.0) was used to evaluate
cross-individual contamination for all sequenced samples with default parameter.
As described [2], ContEst is a GATK module for estimating the level of cross-
sample contamination in next-generation sequencing data based on Bayesian fra-
mework. The input files used were each sample’s bam-file after alignment and
corresponding germline SNV mutation result in vcf format detected by GATK as
described above. The population allele frequency file used during the analysis was
downloaded from the CGA official website along with the ContEst software (http://
software.broadinstitute.org/cancer/cga/contest_download).
SCNA calling
Absolute. We used multiple methods to assess putative cellularity and ploidy.
Firstly, CNVkit was performed to generate segmented logR calls for tumour-
normal pairs, and ABSOLUTE was used to estimate tumour purity, ploidy and
absolute copy number per segment. The ABSOLUTE solutions were reviewed
manually according to the recommended best practice. Beside, as the majority of
ubiquitous mutations are likely clonal, their VAFs (after correcting for copy
number) should reflect the tumour purity, says the maximum peak of variant allele
fraction distribution should equal to one half of the purity. ASCAT/Battenberg
estimates of purity and ploidy were also included to compare with ABSOLUTE
solution. Therefore, we assessed whether the tumour purity and ploidy esimates
from copy number analysis (ABSOLUTE/ASCAT/ Battenberg) were consistent
with VAF estimates among multi-regions. We excluded samples with low purity
and the VAF peak was <0.1, or samples had no concordant solution.
ASCAT. To estimate somatic copy number alternations, ASCAT/Battenberg was
performed on multi-regional paired tumour-normal sequencing data. Allele counts
of positions from 1000 genomes were generated using AlleleCounter, and mini-
mum coverage of 20 for normal sample was used for filtration. LogR and BAF
values were produced for each region, and concatenated into one matrix separately
for each patient. LogR values were subsequently corrected using a GC wave cor-
rection implemented in ASCAT, and only heterozygous BAF values were reserved
for further analysis. Allele-specific multi-sample segmentation was performed to
generate segmented logR and BAF data by ascat.asmultipcf. Both ASCAT and
Battenberg algorithms were applied to provide cellularity (purity) and ploidy
estimates with gamma setting of 1, and manual verification was used to select the
optimal model for ploidy and cellularity using an orthogonal measures based on
ABSOLUTE results and mutation variant allele fraction. And then ASCAT/Bat-
tenberg was re-run to obtain the final allele-specific copy number data using
reviewed cellularity and ploidy. To assess SCNA calls, we compared absolute copy
number profiles using four software packages – ABSOLUTE, CNVKit, ASCAT and
Battenberg. All the samples showed high concordance except patient 12 R1 and R4,
which had no best solution in ABSOLUTE.
Phylogenetics. We used ASCAT (purity, VAF and SCNA) to obtain the cancer cell
fraction (CCF). For each mutation, nmut was calculated. This variable is the product




pCNt þ CNn 1 p
  
ð1Þ
VAF is the variant allele frequency, and p is tumour purity, CNt is the tumour
locus- specific copy number, CNn is the normal locus specific copy number (CNn
= 2). Next, nchr (expected mutation copy number) was calculated using the VAF,
assigning a mutation to one of the possible local integer copy number states, using
maximum likelihood.
PyClone Dirichlet process clustering. Briefly, for each mutation, the observed
variant count was used with a reference corresponding to VAF= 0.5x pre-
clustering CCF, major allele copy number= 2, minor allele copy number= 0 and
purity= 0.5; Clonal versus subclonal mutations were grouped according to pre-
clustering CCF. PyClone was run with the following parameters; 10,000 iterations,
burn-in = 1000, --var_prior = ‘BB’ and –ref_prior = ‘normal’.
Phylogenetic trees. Clonal deconvolution in Pyclone served as an input to gen-
erate phylogenetic trees in CITUP (CITUP, v0.1.1, https://github.com/
amcpherson/citup)50. Default parameters were used for the QIP mode, mutation
clusters and mean CCF as inputs. Mutations< per cluster were filtered and trees
ranked by BIC (Bayesian information) score, with the tree solution being selected at
the minimum. clonevol package51 was used to profile the subclonal architecture in
each tumour region, and trees were drawn using igraph.
Evolutionary cluster inference by transfer learning. REVOLVER was used to
infer repeated evolutionary trajectories in MPM27. This package uses the pigeon-
hole principle and sum rule for phylogenetic construction, and implements a
maximum likelihood (ML) method to jointly fit and identify similar trajectories
among patients by transfer learning. Evolutionary distances between fitted trajec-
tories were computed and used to stratify the cohort into subgroups of tumours
that harbour similar evolutionary trajectories. We jointly considered both somatic
mutations and copy number alternations occurring in NF2, BAP1, FBXW7,
SETD2, LAST2, PTEN and CDKN2A as drivers in MPM. CCF values of mutations
were obtained from PyClone analysis. While SCNAs were assigned to CCF clusters
by present or absent in multi-regions, their CCFs were defined as the mean CCFs of
target cluster. A jackknife approach was applied to estimate the stability of clusters
and trajectories. REVOLVER analysis was conducted in R version 3.5.1.
Prognostic impact of evolutionary clusters was orthogonally validated using the
mesothelioma TCGA dataset27. Briefly, a decision tree was used to bin MPMs in
the TCGA dataset. These clusters were then compared for overall survival using
Kaplan-Meier analysis.
Driver calling. Driver genes were identified combining multiple strategies. Firstly,
dNdScv (https://github.com/im3sanger/dndscv) and MutsigCV(v1.4) were used to
predict driver genes separately based on somatic mutations detected above for the
whole cohort under analysis, both with default parameters. Genes with q-value <
0.05 reported by either methods were considered as candidate driver genes. All
non-silent variants were compared with a potential driver genes list (n= 26),
curated from previous pleural mesothelioma analyses7,52. Any variants with loca-
tion overlap with one of these genes were selected. The newly predicted as well as
reported genes in the literature, comprised our candidate driver gene list. Then,
functional prediction was done to infer whether these candidate driver gene
associated variants were deleterious or not. Four computational approaches were
applied-SIFT, Polyphen (Polyphen2_HDIV and Ployphen2_HVAR), Muta-
tionTaster and CScape (http://www.cscape.biocompute.org.uk). A mutation was
predicted deleterious if results of both CScape and MutationTaster were deleter-
ious, or CScape with low-confidence deleterious but other 3 algorithms were
predicted deleterious.
dN/dS analysis. The dN/dS represents ratio of substitution rates at non-
synonymous sites to those at synonymous sites, estimating positive selection at
mutational level. The dN/dS ratios in this analysis were estimated using the R
package dNdScv (https://github.com/im3sanger/dndscv). We separately ran this
tool on clonal mutation set, subclonal mutation set, as well as total mutations
detected above, with default and recommended parameters.
Mutation signature analysis (v3). COSMIC mutational signatures v3 released 59
Single Base Substitution (SBS) Signatures, which can be used to decipher muta-
tional processes in most cancers, such as DNA mismatch repair deficiency, tobacco
smoking, UV-light exposures and drug treatment. We used R package decon-
structSigs to reconstruct the mutational profiles of each sample based on COSMIC
SBS signatures, which applied a multiple linear regression model to determine the
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activities of pre-defined signatures. For both clonal and subclonal signature ana-
lysis, we excluded samples with mutations less than 50.
HLA typing and HLALOH. HLA typing for MHC class-I genes was carried out
using POLYSOLVER(v1.0) [3] software for all 28 normal-samples’ bam files, with
default parameters. In brief, reads in the WES data potentially originate from HLA
gene region were extracted out and then aligned to genomic sequence library of all
known HLA alleles based on IMGT, using Novoalign packaged in POLYSOLVER.
After which, a two-step Bayesian classification approach was used to infer the two
alleles for each HLA class-I genes (HLA-A, HLA-B and HLA-C). A crucial part of
neoantigen presentation is the HLA class-I genes products, which can present
tumour associated epitopes to T cells and then trigger out immunal response of
body. Loss of heterozygosity in HLA genes may lead to decreased ability to present
productive tumour neoantigens, which could facilitate immune evasion of cancer.
LOHHLA15 (https://github.com/slagtermaarten/LOHHLA) software was used to
evaluate HLA loss for all 118 tumour samples, based on the alignment results of
both tumour and corresponding normal samples, inferred tumour purity and
ploidy information, and the HLA class-I genotyping results detected above. In
brief, HLA reads were extracted and re-aligned to the patient-specific HLA-I alleles,
then HLA gene specific log ratio was calculated based on coverage information on
mismatch positions between homologous HLA alleles, and finally, HLA haplotype
specific copy number was determined. In the analysis, items with PVal_unique
≤0.01 (difference in log ratio between allele 1 and allele 2 ≤0.01) were considered as
a LOH event.
Neoantigen prediction. In this analysis, neoantigens were defined as 8-11-mer
peptides resulted from somatic SNVs or InDels which lead to amino-acid changes
and, binding affinity score between remodelled peptide and respective patient’s
HLA class-I molecules was <500 nM. Somatic mutation VCF files both from
VarScan2 and Mutect2 were annotated by Variant Effect Predictor (Version 84)
with default parameter, except for the using of ‘downstream’ and ‘wild-type’ plu-
gins offer by pVACseq53. After annotation, the variants items lead to peptide
changes were extracted out for downstream analysis. Bam-readcount (0.8.0) was
used to acquire sequencing-based read depth information on each selected variant
for both tumour and matched normal samples. Annotated non-synonymous
mutations, sequencing-based information as well as HLA class-I gene typing results
inferred by POLYSOLVER were feed into pVACseq(4.0.9) for neoantigen pre-
diction. For each pVACseq run, epitope prediction was done by both NetMHC and
NetMHCpan algorithms packed in pVACseq toolkit, epitope length was set to 8–11
and tumour DNA VAF cutoff was set to 10, with default parameters used for all
other settings. Epitope prediction was performed based on the selected prediction
algorithms, after which, sequencing-based information was integrated to enable
filtering of neoantigen candidates (Normal Coverage ≥5X, Normal VAF ≤2%,
Tumour Coverage ≥10X, Tumour VAF ≥10%). Inferred neoantigen candidates
were selected out and those with binding affinity fold change >2 were considered
with higher priority level, which means the ratio of binding affinity score between
wild-type peptide and mutated peptide. The greater this value, the stronger of the
binding affinity after mutation compared with wild-type epitope.
RNA extraction from FFPE. RNA was extracted 30 formalin-fixed paraffin-
embedded (FFPE) tissue blocks. Tumour content was assessed by a pathology. Only
samples with more than 50% tumour content were used for the analysis. RNA
extraction was carried out with the Quiagen RNeasy FFPE kit, according to the
manufacturer’s instructions. Four (4) 10-µm-thick sections from each of the FFPE
tissues blocks were used. Qubit RNA High Sensitivity (HS) Assay Kit and Qubit 4
RNA Integrity and Quality (IQ) Starter Kit (Invitrogen) were used to determine
quantity and quality of RNA, respectively. All samples had an IQ > 5. Samples were
prepared according to the manufacturer’s instructions and read on the Qubit 4
Fluorometer (Invitrogen).
Transcriptome analysis and digital cytometry. Transcriptomic analysis was
performed by Hologic Ltd. Samples (1.7–5.5 µg RNA) were analysed on Human
HT ClariomTM S pico array, (Thermo Fisher) according to the manufacturer’s
instructions. Cel. Files obtained from Clariom S analysis were analysed with
CIBERSORT, a publicly-available deconvolution algorithm that can identify cell
populations and estimate their relative abundances from gene expression data
obtained from bulk tissues (Newman et al. 2015). Algorithm execution and stacked
bar chart creation were performed on the CIBERSORT website: https://cibersort.
stanford.edu/. Resulting figures produced, in R Studio version 1.1.463, running R
version 3.5.2.
Multiplex immunofluorescence based cytometry. Formalin-fixed, paraffin-
embedded (FFPE) sections were cut from MEDUSA22 cohort archival blocks and
subjected to deparaffinisation in an alcohol gradient before rehydration and
washing. Next, endogenous epitopes were exposed by microwaving samples in 1%
Tris-EDTA (pH 9.0) at full power for 20 min. Target-specific staining was achieved
using the Opal fluorescent IHC kit (Akoya Biosciences): Opal protein block was
added to sections before primary antibody incubation to minimise non-specific
staining. Primary antibodies targeted human epitopes of: CD68, clone PG-M1
(diluted 1:500); CD8, clone C8/144B (diluted 1:400); and Pan-cytokeratin, clone
MNF116 (diluted 1:200). All primaries were raised in mice, acquired from Dako
and diluted in PBS. Standard Opal HRP-conjugated secondary antibody polymer
enabled detection of specific primary antibody binding to the target epitope.
Fluorophores used were Opal 520, Opal 570 and Opal 690, respective to primaries
mentioned above. All stained and no-primary control slides received a DAPI
counterstain. Further, unstained sections were prepared as described above, but
without antibody or fluorophore incubation, and used as templates of endogenous
auto-fluorescence to enable more accurate assessment of fluorophore intensity.
Images were obtained using the Vectra Polaris™ multispectral fluorescence
scanner (Akoya Biosciences). The accompanying software, inForm® (Akoya
Biosciences), used a machine learning approach to identify nuclei according to
DAPI intensity and to phenotype cells. During phenotyping, inForm considered
the fluorophore intensity of user-defined positive cells and applied the appropriate
phenotype to unsupervised cells with a similar signal. The R programming
environment (version 3.6.1, manipulated via R Studio 1.2.5001) was used to
measure absolute stained or counterstained cell quantities and compute nearest
neighbours of each phenotype per cell.
Primary cell lines. MED85 (NF2 deleted) and MED96 cells were isolated from
tissue acquired at surgery. Tissue was manually minced on a wax sheet using a
scalpel, placed in HBSS media and incubated for 30 min at room temperature. Cells
were filtered through 100-μm cell strainer and centrifuged at RT, 300 × g for 10
min. The pellet was resuspended in red blood cell lysis buffer and incubated for 10
min. After centrifugation, cell lines were grown with the presence of 10% CO2 on
RPMI medium (31870, Gibco) supplemented with 10% FBS (F9665, Sigma-
Aldrich), 1x GlutaMax (35050038, Gibco) and 1% Penicillin/Streptomycin
(11548876, Gibco). When about 80% confluent, cells have been harvested using 1x
trypsin EDTA solution (15400054, Gibco) and manually counted. Cells were
resuspended in phosphate-buffered saline (10209252, Oxoid) with 0.5% of bovine
serum albumin (A7030, Sigma-Aldrich) and aliquoted 1 × 105 per tube. Prepared
aliquots were incubated for 30 min at 4 °C with anti-human mesothelin phycoer-
ythrin conjugated antibody (R&D systems) and/or anti-podoplanin – APC con-
jugated antibody (Miltenyi biotec), or as an unstained control. Dilution of both
antibodies was 1:10. After incubation samples were washed three times in PBS with
0.5% BSA (5 min at 300xG) and resuspended to final volume of 300 µl. Samples
were acquired on a BD FACS CantoII flow cytometer running BD
FACSDiva8.0.1 software, directly after preparation. Cell population abundance:
MED85 7500 cells with 25.9% positive for mesothelin and 97.7% positive for
podoplanin. MED96 10000 cells with 17.4% positive for mesothelin and 55.7%
positive for podoplanin.
Gating strategy: samples were acquired first on FSC vs SSC and a generous gate
created. Threshold for APC and PE channels were set on unstained controls. Cell
lines were whole-exome sequenced to verify somatic SNV and SCNA profiles
compared with the parental tumours.
Confocal immunofluorescence imaging. MED (MIST) 85 and MED (MIST) 96
cells grown at low densities on sterile glass coverslips were fixed in 4% paraform
aldehyde for 10 min, permeabilized with 0.4% Triton-X100 in PBS for 15 min, and
blocked in 5% BSA for 30 min. Primary antibody staining was performed with anti-
YAP1 antibody (Santa Cruz Biotechnology), for 1 h at room temperature, followed
by secondary staining with chicken anti-mouse IgG (H+L)-AlexaFluor488
(Thermo Fisher Scientific, 1:1000) for 30 min. Cells were counterstained with DAPI
and mounted with ProLong Gold anti-fade reagent (Thermo Fisher Scientific).
Confocal imaging was performed using an Olympus FV1000 confocal laser scan-
ning system with an inverted IX81 motorised microscope equipped with UPlan-
SApo 60×/1.35NA objective (Olympus). Obtained images were deconvoluted using
Huygens Essential software (Scientific Volume Imaging) and processed using
ImageJ software (NIH).
Clinico-pathological variables. Clinical data included related to the date age,
gender, smoking history, asbestos exposure, histological subtype, TMN stage,
receipt of neoadjuvant therapy, laterality of pleural mesothelioma, resection margin
and blood parameters: haemoglobin, platelets, neutrophil and lymphocyte counts,
CRP and LDH. EORTC prognostic score, Neutrophil-to-lymphocyte and platelet-
to-lymphocyte ratios were calculated.
Isolation of plasma and buffy coat from whole blood. Blood samples were
collected in EDTA tubes and blood components (buffy coat and plasma) were
isolated ≤2 h post-venepuncture. Whole blood was firstly centrifuged for 10 min at
1000 × g at 4 °C to separate blood components. Plasma was carefully transferred to
clean plasticware, avoiding visible contamination from the buffy coat and packed
erythrocytes, and then centrifuged for a further 10 min at 2000 ×s g at 4 °C to
exclude any residual cellular matter, before finally being aliquoted into 1.5 mL
tubes. Both centrifugation steps were conducted with the centrifuge brake set to
zero. Leucocytes, a source of germline control DNA, were isolated by carefully
pipetting the buffy coat layer and transferred to 1.5 mL tubes. Both plasma and
buffy coat aliquots were placed at −80 °C for later use.
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cfDNA extraction from plasma. cfDNA was isolated from 3mL plasma using the
QIAamp® Circulating Nucleic Acid Kit (Qiagen) and the QIAvac 24 Plus vacuum
manifold system, according to the manufacturer’s protocol. This kit uses a silica
membrane-based DNA purification technology, where using several washing steps,
contaminants (e.g. proteins, RNA) are effectively removed. Each sample was eluted
in a total volume of 150 µL Buffer AVE and then quantified (see, ‘Quantitation of
cfDNA’). Quantified cfDNA was subsequently stored at 4 °C for immediate use (up
to 6 weeks) or at −20 °C for later use.
Quantitation of cfDNA. Freshly eluted cfDNA was quantified using the 4200
TapeStation System with High Sensitivity D5000 Reagents and ScreenTape (Agi-
lent Technologies), according to the manufacturer’s instructions. In addition to
quantitation values, the TapeStation system provides a fragment size distribution
for each sample. Considering the typical size range of cfDNA to be found between
60 and 300 bp, a region analysis using these boundaries was conducted and this
DNA concentration value was taken forward for subsequent droplet digital PCR
(ddPCR).
Clonal variant selection criteria for cfDNA analysis. The identification of clonal
variants for assay design was determined using the following criteria: (1) absent
from germline DNA, (2) found in all tumour DNA regions, (3) Tier 1 and Tier 2
predicted drivers (Cancer Genome Interpreter) were prioritised and (4) highest
mean VAF amongst tumour regions. If initially selected variants failed QC (see
‘cfDNA assay design and validation’), the criteria were relaxed when required.
cfDNA assay design, validation and optimisation. Oligonucleotides were
designed using the Primer3 tool (Whitehead Institute, MIT). To confirm oligo-
nucleotide specificity, sequences of interest were aligned to the human genome
using the NCBI BLASTN tool. Primer/probe candidate sequences were assessed
using the OligoAnalyzer 3.1 (Integrated DNA Technologies) software, to assess
specificity and to predict their propensity to form hairpins and homodimers/het-
erodimers. Oligonucleotides with a secondary structure ΔG value <−6 kcal/mol
were excluded. Amplicon length was verified using the UCSC in silico PCR tool
using the GRCh37/hg19 reference genome. Where possible, the following para-
meters were adhered to: GC content of 40–60%, length of 15–25 bp, primer Tm of
55–62 °C, probe Tm of 65–72 °C, ≤3 consecutive G/C bases, a GC-clamp of ≤3 G/C
bases and an amplicon length of <100 bp. Desalted primers were delivered lyo-
philised and were subsequently reconstituted using sterile TE Buffer (Invitrogen) to
a stock concentration of 200 µM.
Primers were validated using Fast SYBR® Green melt curve analysis (qPCR),
prior to the introduction of the probe, in order to assess primer specificity,
efficiency and potential secondary structure formation. Each primer was diluted to
a working stock of 10 µM and a standard curve was constructed using serially
dilutions (1:2 dilution; 7 points) Human Genomic DNA (Roche) ranging from 20
to 0.3125 ng per well. Each of the serial concentrations were run in triplicate, with a
no template control (NTC). A total reaction volume of 10 µL comprised 5 µL Fast
SYBR® Green Master Mix (2X) (Applied Biosystems), 0.6µL forward primer
(600nM final concentration), 0.6 µL reverse primer (600 nM final concentration),
0.2 µL sterile TE Buffer (Invitrogen) and 3.6 µL template DNA. Reactions were set
up in MicroAmp® Fast Optical 96-well reaction plates (Applied Biosystems), sealed
with MicroAmp® adhesive film (Applied Biosystems), centrifuged and run on the
StepOnePlusTM Real-Time PCR System (Applied Biosystems) under the following
conditions; 95 °C for 20 s, 50 cycles of 95 °C for 3 s and 60 °C for 30 s and finally a
dissociation (melt) curve step. An efficiency value of 90–110% and an R2 > 0.98 was
considered acceptable. Secondary products, where applicable were identified
through the inspection of the melt curve and those identified to have significant
non-specific products were redesigned as required.
Assays were optimised by ddPCR through a temperature gradient (53–63 °C) in
order to identify the optimum annealing temperature (Ta) of each assay. Optimal
Ta was defined by the temperature which allowed the largest discrimination
between positive and negative droplets, whilst avoiding non-specific amplification.
Droplet digital PCR. Inhouse designed assays each included common forward and
reverse primers, with allele-specific (mutant and wild type) probes (see supple-
mentary data 11, for oligonucleotide sequences). In all, 20 µL individual reaction
mixes contained the following: 10 µL ddPCR Supermix for Probes (No dUTP)
(Bio-Rad), 1 µL mutation assay (20X) and 9 µL of template DNA/H2O. For tumour
and germline DNA, 10 ng DNA was loaded into each reaction. For cfDNA, a
higher quantity of 20 ng was loaded as a means of achieving a lower limit of
detection (LOD). Each 20 µL reaction was loaded into a DG8TM Cartridge (Bio-
Rad) along with 70 µL Droplet Generation Oil for Probes (Bio-Rad), then sealed
using a DG8TM gasket (Bio-Rad). Sealed cartridges were then placed into the
QX200TM Droplet Generator (Bio-Rad), to allow the generation of >10,000
nanolitre sized emulsion droplets, according to the manufacturer’s instructions.
Following this, generated droplets were carefully transferred to Twin-Tec 96-
Well × 250 µL Semi-Skirted PCR plates (Eppendorf) and sealed with a Pierceable
Foil Heat Seal (Bio-Rad) at 180 °C using the PX1TM PCR Plate Sealer (Bio-Rad).
The sealed plates then underwent PCR in the C1000 TouchTM Thermal Cycler
(Bio-Rad) with the following conditions; 95 °C for 10 min, 40 cycles of 94 °C for
30 s and Ta (assay dependent, range 54 °C–63 °C) for 1 min and then 98 °C for 10
min, before cooling to 4 °C. Post-PCR, plates were analysed on the QX200TM
Droplet Reader (Bio-Rad) using the QuantaSoftTM Software v1.7 (Bio-Rad) on the
Rare Event Detection settings for mutation detection. The number of positive
droplets for mutant and wild type (WT) were used to calculate the VAF of
respective mutations.
Statistical analysis. All statistical analyses involving clinical, immune and clonal
architecture characteristics were performed in R Studio, version 1.2.5001, running
R version 3.6.1. Due to the relatively small patient cohort, continuous variables
were tested for normality using Shapiro-Wilk’s test (‘shapiro.test’ in base R). Only
half of all continuous variables were normally distributed according to Shapiro-
Wilk’s test, so correlations were investigated using Spearman’s rank correlation
test (‘rcorr’ in the package ‘Hmisc’). Differences in medians (for skewed distribu-
tions) were uncovered using the Wilcoxon rank-sum test (‘wilcox.test’ in base R),
while means were compared (where both populations relating to a category obeyed
a normal distribution) using Welch’s t-test (‘t.test’ in base R with ‘var.equal’=-
FALSE) because samples were not paired and typically of different sizes. Similarly,
multi-categorical medians were compared using the Kruskal-Wallis rank-sum test
(‘kruskal.test’ in base R). For categorical variables, statistical significance was
interrogated using Fisher’s exact test due to frequent small group sizes (‘fisher.test’
in base R). All derivative figures were generated using the package ‘ggplot2’. Sur-
vival analysis was conducted using the log-rank test (built into ‘ggsurvplot’ in the
package ‘survminer’, which was also used to plot survival curves), with Kaplan-
Meier curves created using ‘survfit’ from the package ‘survival’.
For ctDNA analysis GraphPad Prism 7 (GraphPad Prism Software Inc., CA,
USA) was used for statistics tests including Wilcoxon rank-sum test
(Mann–Whitney U test). Any P values were considered significant if <0.05.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The main data supporting the results are available within this article and its
supplementary information.
The raw sequencing is available in SRA Run Selector via [https://www.ncbi.nlm.nih.
gov/sra/?term=PRJNA649889] or [https://www.ncbi.nlm.nih.gov/sra/?
term=SRP276753] which is hosted by the national Centre for Biotechnology
Information, under accession number PRJNA649889. The data is searchable in Entrez via
[https://www.ncbi.nlm.nih.gov/sra/?term=PRJNA649889]. All of the other data
supporting the findings of this study are available within the article and its
supplementary information files and from the corresponding author upon reasonable
request.
Code availability
Scripts related to clonality analysis, mutational signatures, dn/dS analysis and
REVOLVER can be accessed via [https://github.com/zanmer/
Mesothelioma_evolution_deciphering_drugable_somatic_alterations], DOI [https://doi.
org/10.5281/zenodo.4305392]
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